1
|
Ma J, Wei Y, Zhang X, Lin L, Bao Y, Cao H, Chen H, Yu J, Yang J, Zhang Y, Lan H, Li X, Qiong H, Yang D, Yu Y, Chen J, Zhang C, liu L, Chen L, Zhan R, Liu F. Enhanced EPR effects by tumour stromal cell mimicking nanoplatform on invasive pituitary adenoma. Mater Today Bio 2024; 24:100895. [PMID: 38179430 PMCID: PMC10765248 DOI: 10.1016/j.mtbio.2023.100895] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Revised: 11/22/2023] [Accepted: 11/29/2023] [Indexed: 01/06/2024] Open
Abstract
Rapid advances in nanomedicine have enabled potential applications in cancer therapy. The enhanced permeability and retention (EPR) effect is the primary rationale for the passive targeting of nanoparticles in oncology. However, growing evidence indicates that the accumulation of nanomaterials via the EPR effect could be more efficient. Inspired by our clinical observation of the Gap Junction connecpion between folliculostellate cells and pituitary adenoma cells, we designed a novel drug delivery system that targets tumours by coating folliculostellate cell (FS) membranes onto PLGA nanoparticles (NPs). The resulting FSNPs, inheriting membrane proteins from the folliculostellate cell membrane, significantly enhanced the EPR effect compared to nanoparticles without cancer cell membranes. We further demonstrated that mitotane encapsulation improved the therapeutic efficacy of mitotane in both heterotopic and orthotopic pituitary adenoma models. Owing to its significant efficacy, our FS cell membrane-coated nanoplatforms has the potential to be translated into clinical applications for the treatment of invasive pituitary adenoma.
Collapse
Affiliation(s)
- Junning Ma
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Department of Neurosurgery of First affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhe Jiang, 310003, China
- Sun Yat-Sen University, Guangzhou, 510275, China
- Department of Pathology& Pathophysiology and Department of Surgical Oncology of Second Affiliated Hospital, Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Yin Wei
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Xiaojian Zhang
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| | - Lu Lin
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| | - Youmei Bao
- School of Medicine Yale University, New Haven, CT, 06510, USA
| | - Hui Cao
- Department of Neurosurgery of First affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhe Jiang, 310003, China
| | - Honghwei Chen
- Department of Neurosurgery of First affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhe Jiang, 310003, China
| | - Jianbo Yu
- Department of Neurosurgery of First affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhe Jiang, 310003, China
| | - Jiqi Yang
- Department of Neurosurgery of First affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhe Jiang, 310003, China
| | - Yue Zhang
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| | - Huimin Lan
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| | - XueYang Li
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| | - Huang Qiong
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Dan Yang
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Yajun Yu
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Jingyao Chen
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Chengchen Zhang
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Li liu
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
| | - Lei Chen
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| | - Renya Zhan
- Zhejiang University School of Medicine, Zhe Jiang, 310003, China
- Department of Neurosurgery of First affiliated Hospital, Zhejiang University School of Medicine Hangzhou, Zhe Jiang, 310003, China
| | - Fei Liu
- Department of Neurosurgery of Fifth affiliated Hospital, SunYat-Sen University Zhuhai, 519000, ZhuHai, China
- Sun Yat-Sen University, Guangzhou, 510275, China
| |
Collapse
|
2
|
Ren B, Xu J, Liu C. Rapid and Practical Synthesis of gem-Dibromoalkanes from Aldehydes by Tribromide Reagent. Chem Asian J 2024:e202301087. [PMID: 38183358 DOI: 10.1002/asia.202301087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 01/05/2024] [Accepted: 01/05/2024] [Indexed: 01/08/2024]
Abstract
gem-Dibromoalkanes are important synthetic building block in organic chemistry, but their preparation is still troublesome. Herein, we have developed a simple and practical protocol for the synthesis of gem-dibromoalkanes from aldehydes using tetrabutylammonium tribromide and triphenyl phosphite. A variety of alkyl and aromatic aldehydes can be transformed into the corresponding products within 10 minutes. This protocol is also applicable to alcohols, and the configuration of chiral alcohol is inverted during the process with excellent enantiopurity.
Collapse
Affiliation(s)
- Bowen Ren
- State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, P. R. China
- University of Chinese Academy of Sciences, Beijing, 100049, P. R. China
| | - Jianeng Xu
- State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, P. R. China
| | - Chao Liu
- State Key Laboratory for Oxo Synthesis and Selective Oxidation, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou, 730000, P. R. China
| |
Collapse
|
3
|
Kawada M, Atsumi S, Wada SI, Sakamoto S. Novel approaches for identification of anti-tumor drugs and new bioactive compounds. J Antibiot (Tokyo) 2017; 71:ja201797. [PMID: 28852178 DOI: 10.1038/ja.2017.97] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Revised: 07/02/2017] [Accepted: 07/17/2017] [Indexed: 12/18/2022]
Abstract
Thanks to the pioneering work done by Professor Hamao Umezawa, bioactive compounds have been used in treatment of several diseases including cancer. In this review, we discuss our work, which focuses on developing new candidates for anti-tumor drugs by screening for bioactive natural compounds in microbial cultures using unique experimental systems. We summarize our recent progress including the following: (1) small-molecule modulators of tumor-stromal cell interactions, (2) inhibitors of three-dimensional spheroid formation of cancer cells, (3) multi-cancer cell panel screening and (4) new experimental animal models for cancer metastasis.The Journal of Antibiotics advance online publication, 30 August 2017; doi:10.1038/ja.2017.97.
Collapse
Affiliation(s)
- Manabu Kawada
- Laboratory of Oncology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Tokyo, Japan
- Numazu, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Shizuoka, Japan
| | - Sonoko Atsumi
- Laboratory of Oncology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Tokyo, Japan
| | - Shun-Ichi Wada
- Laboratory of Oncology, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Tokyo, Japan
| | - Shuichi Sakamoto
- Numazu, Institute of Microbial Chemistry (BIKAKEN), Microbial Chemistry Research Foundation, Shizuoka, Japan
| |
Collapse
|
4
|
Scott MC, Tomiyasu H, Garbe JR, Cornax I, Amaya C, O'Sullivan MG, Subramanian S, Bryan BA, Modiano JF. Heterotypic mouse models of canine osteosarcoma recapitulate tumor heterogeneity and biological behavior. Dis Model Mech 2016; 9:1435-1444. [PMID: 27874835 PMCID: PMC5200896 DOI: 10.1242/dmm.026849] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2016] [Accepted: 09/23/2016] [Indexed: 01/03/2023] Open
Abstract
Osteosarcoma (OS) is a heterogeneous and rare disease with a disproportionate impact because it mainly affects children and adolescents. Lamentably, more than half of patients with OS succumb to metastatic disease. Clarification of the etiology of the disease, development of better strategies to manage progression, and methods to guide personalized treatments are among the unmet health needs for OS patients. Progress in managing the disease has been hindered by the extreme heterogeneity of OS; thus, better models that accurately recapitulate the natural heterogeneity of the disease are needed. For this study, we used cell lines derived from two spontaneous canine OS tumors with distinctly different biological behavior (OS-1 and OS-2) for heterotypic in vivo modeling that recapitulates the heterogeneous biology and behavior of this disease. Both cell lines demonstrated stability of the transcriptome when grown as orthotopic xenografts in athymic nude mice. Consistent with the behavior of the original tumors, OS-2 xenografts grew more rapidly at the primary site and had greater propensity to disseminate to lung and establish microscopic metastasis. Moreover, OS-2 promoted formation of a different tumor-associated stromal environment than OS-1 xenografts. OS-2-derived tumors comprised a larger percentage of the xenograft tumors than OS-1-derived tumors. In addition, a robust pro-inflammatory population dominated the stromal cell infiltrates in OS-2 xenografts, whereas a mesenchymal population with a gene signature reflecting myogenic signaling dominated those in the OS-1 xenografts. Our studies show that canine OS cell lines maintain intrinsic features of the tumors from which they were derived and recapitulate the heterogeneous biology and behavior of bone cancer in mouse models. This system provides a resource to understand essential interactions between tumor cells and the stromal environment that drive the progression and metastatic propensity of OS. Editors' choice: We developed a system that recapitulates the heterogeneous biological behavior of bone cancer in mouse models and describe novel methods to study tumor–stromal interactions in these models.
Collapse
Affiliation(s)
- Milcah C Scott
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
| | - Hirotaka Tomiyasu
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
| | - John R Garbe
- Minnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA
| | - Ingrid Cornax
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA
| | - Clarissa Amaya
- Department of Biomedical Sciences, Center of Emphasis in Cancer Research at the Paul Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
| | - M Gerard O'Sullivan
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Department of Veterinary Population Medicine, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA
| | - Subbaya Subramanian
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Department of Surgery, School of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
| | - Brad A Bryan
- Department of Biomedical Sciences, Center of Emphasis in Cancer Research at the Paul Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX 79905, USA
| | - Jaime F Modiano
- Animal Cancer Care and Research Program, University of Minnesota, St Paul, MN 55108, USA .,Department of Veterinary Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St Paul, MN 55108, USA.,Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.,Stem Cell Institute, University of Minnesota, Minneapolis, MN 55455, USA.,Center for Immunology, University of Minnesota, Minneapolis, MN 55455, USA
| |
Collapse
|